Literature DB >> 36261703

Subclinical Leaflet Thrombosis in Supra-annular Transcatheter Aortic Valves: the Role of Leaflet Design.

Dong Qiu1, Ali N Azadani2.   

Abstract

Subclinical leaflet thrombosis has been increasingly observed in patients undergoing transcatheter aortic valve replacement. Intra-annular transcatheter aortic valves (TAVs) have a larger neo-sinus volume than supra-annular devices and are potentially at a higher risk of hypoattenuated leaflet thickening (HALT). However, clinical data from randomized clinical trials have shown that approximately one-third of patients undergoing TAVR with intra- or supra-annular devices develop HALT in 1 year. The findings point to the potential role of leaflet design in developing HALT. The study aimed to systematically investigate leaflet kinematics of a supra-annular TAV, Medtronic CoreValve, and determine regions of blood stasis. Fluid-solid interaction simulations demonstrated the limited movement of CoreValve leaflets in the lower belly region that created regions of blood stasis on the surface of the leaflets. The findings provide insights into potential improvements in leaflet design in the next generation of TAVs to reduce the risk of HALT and leaflet immobility.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Flow stasis; Hypoattenuated leaflet thickening; Leaflet design; Neo-sinus; Subclinical leaflet thrombosis; Transcatheter aortic valve replacement

Year:  2022        PMID: 36261703     DOI: 10.1007/s12265-022-10333-x

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   3.216


  1 in total

1.  Valve thrombosis following transcatheter aortic valve replacement: significance of blood stasis on the leaflets.

Authors:  Koohyar Vahidkhah; Mohammed Barakat; Mostafa Abbasi; Shahnaz Javani; Peyman N Azadani; Anwar Tandar; Danny Dvir; Ali N Azadani
Journal:  Eur J Cardiothorac Surg       Date:  2017-05-01       Impact factor: 4.191

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.